These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 28882555)
1. Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. Prekovic S; Van den Broeck T; Moris L; Smeets E; Claessens F; Joniau S; Helsen C; Attard G Mol Cell Endocrinol; 2018 Feb; 462(Pt A):56-63. PubMed ID: 28882555 [TBL] [Abstract][Full Text] [Related]
2. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. Mollica V; Di Nunno V; Santoni M; Cimadamore A; Scarpelli M; Lopez-Beltran A; Cheng L; Mariani C; Battelli N; Montironi R; Massari F Expert Rev Mol Diagn; 2020 Feb; 20(2):207-217. PubMed ID: 31640441 [No Abstract] [Full Text] [Related]
3. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine? Miyamoto DT; Lee RJ Urol Oncol; 2016 Nov; 34(11):490-501. PubMed ID: 27771279 [TBL] [Abstract][Full Text] [Related]
5. Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Vandekerkhove G; Chi KN; Wyatt AW Cancer Genet; 2018 Dec; 228-229():151-158. PubMed ID: 28958406 [TBL] [Abstract][Full Text] [Related]
6. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer. Morrison GJ; Goldkorn A Curr Oncol Rep; 2018 Mar; 20(4):35. PubMed ID: 29572775 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311 [TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy: ready to guide therapy in advanced prostate cancer? Hegemann M; Stenzl A; Bedke J; Chi KN; Black PC; Todenhöfer T BJU Int; 2016 Dec; 118(6):855-863. PubMed ID: 27430478 [TBL] [Abstract][Full Text] [Related]
9. Using circulating cell-free DNA to monitor personalized cancer therapy. Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575 [TBL] [Abstract][Full Text] [Related]
10. Fundamentals of liquid biopsies in metastatic prostate cancer: from characterization to stratification. van Dessel LF; Martens JWM; Lolkema MP Curr Opin Oncol; 2020 Sep; 32(5):527-534. PubMed ID: 32675591 [TBL] [Abstract][Full Text] [Related]
11. Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. Friedlander TW; Pritchard CC; Beltran H Am Soc Clin Oncol Educ Book; 2017; 37():358-369. PubMed ID: 28561699 [TBL] [Abstract][Full Text] [Related]
18. Application of liquid biopsy in precision medicine: opportunities and challenges. Wang J; Chang S; Li G; Sun Y Front Med; 2017 Dec; 11(4):522-527. PubMed ID: 28744793 [TBL] [Abstract][Full Text] [Related]
19. Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Culig Z; Hobisch A; Hittmair A; Peterziel H; Radmayr C; Bartsch G; Cato AC; Klocker H Histol Histopathol; 1997 Jul; 12(3):781-6. PubMed ID: 9225161 [TBL] [Abstract][Full Text] [Related]
20. Androgen Control in Prostate Cancer. Pelekanou V; Castanas E J Cell Biochem; 2016 Oct; 117(10):2224-34. PubMed ID: 27104784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]